Formulation, run as a controlled science.

A working in-house lab, named scientists, and validated analytical methods — so a new product moves from concept to consistent commercial batches without ever leaving the system.

Most oral-product programs stall in development — not production.

Getting an active to perform consistently, mask cleanly, release predictably and survive shelf life is where products are won or lost. Pouchtech™ runs that work in-house, on the same controlled architecture that makes the product — so development decisions carry straight through to commercial scale with nothing lost in hand-off.

The result for partners:

  • Development and manufacturing in one controlled system — no translation loss at scale-up
  • Decisions backed by analytical data, not opinion
  • A clear, honest view of what runs today and what is in build
  • A single accountable team from first feasibility batch to commercial supply

Capabilities

MCC-based matrix development for nicotine, caffeine and functional blends. Custom strengths and pouch formats developed and verified by HPLC, then validated for batch-to-batch reproducibility before scale-up.

An in-house analytical lab running nicotine uniformity, pH, moisture and in-process controls at every stage. GMP-aligned method development is expanding to GC-MS, FTIR, DSC and dissolution as the lab builds out through 2026.

In-vitro release-rate measurement in biorelevant media — the science that lets us characterise and tune how an active is delivered over time. For functional formats, release behaviour is the product experience.

Real masking engineering for difficult actives — bitter and hygroscopic ingredients such as amino acids and functional actives — developed through our specialist network and an expanding in-house capability. Depth, not a flavour drop-in.

We develop our own nonwoven substrate, so material is a controllable development lever, not a bought-in constant. Tunable GSM (28–36 g/m²) and controlled hydrophilicity let us engineer product feel and release. Food-contact certified (EU EC 1935/2004, EU 10/2011; US FDA 21 CFR 177.1630); REACH / SVHC below 0.1% (SGS-tested).

A formal stability program — real-time and accelerated — to establish shelf-life and retest intervals. The evidence base regulated-market launches require.

How development works

Feasibility → Formulation → Pilot batch → Process validation → Stability → Commercial scale

Each gate is documented and data-backed. With our pilot / trial line we allow our partners R&D teams to run their own trials, allowing them to iterate on our line directly, lowering NPI risk and shortening the path to a validated product.